From raw botanical characterization to pilot-scale cGMP clinical trial batch supplies and multi-center clinical execution, explore our core specialized solutions designed for worldwide pharmaceutical innovators.
Phase II clinical trials represent the ultimate litmus test in translational drug development. In natural medicine, proof-of-concept (PoC) demands overcoming complex chemical heterogeneity, dose-response non-linearity, and stringent multi-regional regulatory harmonizations.
For botanical drugs, phytochemical entities, and modernized Traditional Chinese Medicine (TCM) compounds, this challenge is multiplied exponentially. Unlike synthetic small molecules characterized by single, isolated target mechanics, natural medicinal preparations frequently operate via polypharmacology—exerting simultaneous modulatory actions on multiple cellular pathways, cytokine cascades, and receptor networks. Consequently, establishing clear dose-response relationships demands analytical and clinical methodologies that go far beyond standard protocols.
MedGence (Yineng Pharma), backed by over 14 years of dedicated contract research and manufacturing execution in Changsha, Hunan, operates as a premier Tier-1 Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in China. By combining rigorous cGMP pilot-manufacturing infrastructure with verified clinical trial execution capabilities across Grade-3A clinical hospitals, MedGence solves the core systemic vulnerabilities that lead to Phase II attrition.
Core Industry Imperative: The U.S. FDA Botanical Drug Guidance, the European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC), and China's National Medical Products Administration (NMPA) center their evaluations on continuous batch-to-batch chemical equivalence. Clinical efficacy demonstrated in Phase II is invalid if the Investigational Medicinal Product (IMP) cannot be quantitatively reproduced at commercial CDMO scale.
Our macro industry solution bridges chemical characterization, preclinical toxicological profiling, and adaptive clinical trial designs into a singular, synchronized workflow. Through high-resolution chromatographic fingerprinting (HPTLC, HPLC-DAD, LC-MS/MS), automated process analytical technology (PAT), and rigorous clinical site management under ICH E6(R2)/(R3) standards, we provide overseas sponsors with unassailable empirical data packages capable of withstanding the scrutiny of FDA, EMA, and NMPA audits alike.
Botanical therapeutics suffer from geo-climatic variation. We deploy multi-origin sourcing matrices, harvesting window optimization, and 2D-chromatographic fingerprinting to guarantee that Phase II trial supplies possess absolute constituent consistency.
To mitigate clinical attrition, we implement Bayesian response-adaptive randomization and Simon’s two-stage trial frameworks. This allows early futility stops and rapid identification of the true minimum effective clinical dose.
We generate dual-language, ICH-standardized electronic Common Technical Documents (eCTD). Our trial data meets concurrent criteria for China NMPA registrations, U.S. FDA IND/NDA submissions, and EMA herbal medicinal dossiers.
Embracing AI-driven quantitative systems pharmacology, patient stratification biomarkers, decentralized trial management, and multi-omics readouts to redefine clinical trial velocity.
Integrating Quantitative Systems Pharmacology (QSP) with neural network algorithms to simulate multi-target ligand-receptor interactions across complex natural mixtures, predicting optimal human dosage regimes prior to first patient enrollment.
Deploying untargeted metabolomics, single-cell RNA sequencing, and clinical proteomics to isolate quantifiable surrogate endpoints, validating biological mechanism-of-action in heterogeneous patient cohorts during Phase IIa exploration.
Leveraging secure cloud-based Electronic Data Capture (EDC), remote patient telemetry, and electronic patient-reported outcomes (ePRO) across multi-regional hospital sites to slash drop-out rates and compress trial timelines by over 35%.
Utilizing 3D patient-derived intestinal, hepatic, and tumor organoids to evaluate individual metabolic variation and toxicological thresholds before expanding Phase II clinical arms, ensuring elevated subject safety profiles.
| Evaluation Parameter | Legacy Phase II Research Approach | MedGence Intelligent Phase II Framework | Client Commercial Gain |
|---|---|---|---|
| Dosage Selection | Empirical trial-and-error escalation cohorts | In silico PK/PD & QSP multi-target algorithmic mapping | Reduces dose-escalation cycle time by 4.5 months |
| IMP Standardization | Single-marker HPLC titration; high lot variance | Comprehensive multi-wavelength chromatographic fingerprinting | Full regulatory acceptance across FDA, EMA & NMPA |
| Patient Stratification | Broad, unstratified clinical symptomatic diagnosis | Multi-omics genomic & metabolomic biomarker selection | Elevates Phase II proof-of-concept success rate by >40% |
| Data Governance | Fragmented local site EDC; delayed manual reconciliation | 21 CFR Part 11 compliant real-time eSource & centralized eTMF | Instant audit-readiness and automated NDA data conversion |
From raw agricultural provenance to finished clinical dosage forms: how MedGence integrates high-precision pilot CDMO manufacturing to ensure uninterrupted Phase II Investigational Medicinal Product supplies.
A key stumbling block for international clinical sponsors is the inability to source Phase II clinical supplies (Investigational Medicinal Products, or IMPs) from facilities that mirror future commercial production parameters. Splitting preclinical extraction from clinical trial manufacturing generates unacceptable chemistry, manufacturing, and controls (CMC) discrepancies.
MedGence operates high-specification pilot plants and coordinated production facilities directly governed by our in-house scientific leadership team. Equipped with automated dynamic extraction batteries, supercritical CO2 extractors, multi-stage macroporous resin separation columns, and high-efficiency freeze-drying systems, we deliver pilot batches that scale seamlessly to commercial metric tons.
Whether delivering active pharmaceutical ingredients (APIs) as standardized concentrated liquids, spray-dried crystalline powders, purified fractions, or volatile essential oils, our operations maintain rigorous environmental controls within ISO Class 7 (Class 10,000) cleanroom suites.
Under the China Factory 4.0 paradigm, our manufacturing process study for botanical active ingredients leverages Process Analytical Technology (PAT). Using real-time Near-Infrared (NIR) spectroscopic probes and automated high-pressure liquid chromatography monitoring directly within extraction tanks, critical quality attributes (CQAs) are measured continuously.
This continuous monitoring eliminates batch-to-batch deviations caused by natural variations in raw plant tissues, solvent temperature fluctuations, or filtration flow differentials. Our automated Closed-Loop Control Systems immediately compensate for process variations, assuring international auditors of unequivocal product homogeneity.
Finished IMP formulations are packaged under double-blind clinical packaging protocols—offering matching placebos (matching in organoleptic profile, color, taste, and density) in oral liquids, enteric-coated capsules, softgels, micro-tablets, and dispersible granules.
China's fully integrated chemical and agricultural infrastructure allows MedGence to deliver cGMP-grade Phase II clinical trial supplies at a 40–60% cost reduction compared to European or North American contract manufacturers.
We control upstream sourcing via audited Good Agricultural and Collection Practices (GACP) farms across authentic Chinese medicinal regions (Daodi herbs), providing complete pedigree records for heavy metals, pesticides, and microbial bioburden.
Integrated cryogenic and temperature-monitored distribution systems guarantee that fragile phytochemical metabolites reach multi-site trial centers with unbroken stability certificates and real-time GPS tracking.
Navigating NMPA regulatory filings, HGRAC biosafety clearances, and strict intellectual property protections for foreign biopharma enterprises entering China clinical ecosystems.
Our on-the-ground regulatory team maintains active communication channels with the Center for Drug Evaluation (CDE) of the NMPA. All trial designs, institutional ethics committee (IEC) dossiers, and clinical operational sites follow strict Good Clinical Practice (GCP) requirements, ensuring total data interchangeability with Western regulatory bodies.
Conducting clinical trials in China involving foreign entities requires navigating the Human Genetic Resources Administration of China (HGRAC) approvals. MedGence possesses established protocols to process international genetic clearance filings rapidly, preventing bureaucratic trial delays for global sponsors.
Intellectual property protection is the cornerstone of our contract research philosophy. We enforce segregated laboratory access, physical air-gapped compute nodes, encrypted molecular databases, and binding Non-Disclosure Agreements (NDAs) that hold full legal enforceability in both Chinese and international courts.
ICH E6(R2)/(R3) & ALCOA+ Data Integrity Standard: MedGence enforces strict compliance with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available). Every assay, patient interaction, temperature log, and chromatogram is permanently audited through cryptographic blockchain timestamps and validated 21 CFR Part 11 compliant audit trails.
A methodical operational matrix for pharmaceutical procurement heads, R&D directors, and clinical program executives evaluating Chinese Phase II trial partners.
Demand concrete milestones: Does the vendor offer end-to-end integration from raw herb potency evaluation, analytical HPTLC/HPLC standard setting, LD50/toxicity profiling, to direct hospital preparation registration? MedGence delivers a defined, legally binding deliverable package at every gate.
Ensure that botanical IMP batches are quantified not by single surrogate markers, but by full chromatographic fingerprint similarity coefficients (>0.95). Inability to provide fingerprint overlays will stall U.S. FDA IND approval packages or European decentralized applications.
Evaluate clinical network reach: MedGence collaborates directly with top provincial TCM academies, university hospitals, and Grade-3A clinical institutions throughout China, giving sponsors rapid, unhindered recruitment access to high-incidence patient cohorts.
Verifiable metrics accumulated over 14+ years of scientific leadership, partnering with premier pharmaceutical enterprises and leading academic hospitals in China.
Our clinical trial protocols, analytical dossiers, and manufacturing systems power programs for China's most esteemed medical and pharmaceutical institutions.
Beijing Tongrentang Group
CR Sanjiu Pharmaceutical
Sunflower Pharmaceutical
Livzon Pharmaceutical
Dihon Pharmaceutical
Golden Throat Group
Yangtzi River Pharma
Beihai Gofar Chuanshan
Humanwell Healthcare
SCIMYTH Pharmaceutical
Shandong Hanfang Pharma
Luoxin Pharmaceutical
Zhongsheng Pharmaceutical
Hunan B&A Herbal Med
Apeloa Pharmaceutical
Heng Chang Pharma
Baotou TCM Co.
Kamp Medicine
Guangxi Santo Pharma
Hunan Kangshou Pharma
Jiangxi Juwang Pharma
Beijing Tcmages Pharma
Guizhou Ruihe Pharma
Anhui CR Jinchan
Kangmei Pharmaceutical
Tianjicaotang Pharma
Kingstone Unite Pharma
Shuguang Hospital, Shanghai
Hunan Directly Affiliated TCM
1st Hospital of Hunan TCM
Second Xiangya Hospital
2nd Hospital of Hunan TCM
Orthopedics of TCM Zhuzhou
Rigorous responses addressing critical regulatory, methodological, and manufacturing questions encountered by global biopharmaceutical procurement teams.
Select any specialized R&D or manufacturing division below to review full technical parameters, instrumentation capacities, and direct procurement documentation.
Engage our senior scientific committee directly to request RFP scoping, protocol feasibility assessments, or pilot-scale Investigational Medicinal Product manufacturing estimates. Our team responds within 24 business hours.
